Dr. William J. Polvino, M.D.
Dr. Polvino joined Veloxis in September 2009 bringing extensive experience in the senior management of pharmaceutical companies together with solid operational experience in drug development and specialty pharma strategy. Earlier in his career, Dr. Polvino was CEO at Helsinn Therapeutics US, Inc (a private company), formerly Sapphire Therapeutics. At Sapphire, he helped drive novel in-licensed new chemical entities into late-stage clinical development, successfully leading the company through acquisition to Helsinn Therapeutics US in January 2009.
Dr. Polvino began his career in the life science industry following his professional training in Internal Medicine at Massachusetts General Hospital and his fellowship in Clinical Pharmacology at the National Institute of Health, USA.
Dr. Polvino has held various senior positions of increasing responsibility within drug development and executive functions at Merck, Wyeth and Theravance prior to joining Sapphire Therapeutics in 2002. Dr. Polvino holds six issued US patents and corresponding international counterparts.
Mr. Stilou joined Veloxis in April 2008. He is responsible for the activities within Finance, IT, Legal Affairs, and Investor Relations.
Dr. John Weinberg
Dr. Weinberg joined Veloxis in July 2010. He is responsible for managing all Commercial activities supporting the Veloxis portfolio of compounds in development. Additionally, Dr. Weinberg directs Corporate Strategy and Pipeline Target Identification.
Ms. Sylvest joined Veloxis in April 2008. She is responsible for clinical development, clinical operations and drug supply.
Mr. Breian Knudsen
Mr. Knudsen joined Veloxis in November 2007. He is responsible for technology transfer, process validation, clinical and commercial manufacturing.
Mr. Knudsen has an extensive experience within process and product development, technology transfer, process validation and manufacture within the pharmaceutical industry.
Prior to joining Veloxis, Mr. Knudsen held a position as Principal Scientist, Chemistry Manufacturing & Controls (CMC) project manager at Novo Nordisk A/S where he headed the CMC part of a number of solid dosage development projects and where he implemented guidelines for systematic in-house and external transfer of manufacturing processes.
Mr. Knudsen holds an MSc in pharmacy from the Pharmaceutical University of Copenhagen.
Ms. Mc Guinness is joined Veloxis in May 2014 bringing 15+ years of experience in regulatory, quality and compliance roles within the pharmaceutical industry. Prior to joining Veloxis, Ms. Mc Guinness held the position of Senior Director of Regulatory Conformance at Mylan, where she established the global regulatory conformance function and team, deployed global processes and systems, and drove strategic regulatory, quality and compliance projects. Prior to joining Mylan, Ms. Mc Guinness held various positions of increasing responsibility at PA Consulting, Accenture (formerly Octagon Research Solutions), Sanofi, Liquent (a Paraxel company) and Ranbaxy Pharmaceuticals Inc.
Ms. Mc Guinness has participated in a number of joint industry-agency initiatives. She was awarded the FDA Commissioner’s Special Citation for her contribution the development of the HL7 Structured Product Labeling standard & FDA guidance.
Ms. Mc Guinness holds an MSc in Quality Assurance/Regulatory Affairs from the Temple University School of Pharmacy. She holds a BA in Biology-Biotechnology from Kean University and is RAC-US certified.
Ms. Mc Guinness is passionate about supporting the rare diseases and orphan indication communities. She volunteers as a director of the Southeastern PA Chapter of Huntington’s Disease Society of America (HDSA) and is a scientific advisor for the CADASIL Association.
Mar 4, 2015
Release of Annual Report 2014
Mar 26, 2015
Annual General Meeting